NRG-GU011
Open to Accrual
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy with or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
Principal Investigator
Status
Open to Accrual
Date Opened To Accrual
December 8, 2021
Disease Site
Genitourinary [GU] Prostate
Phase
II
Developmental Therapeutics
Yes
Primary Objective
Compare conventional radiological progression-free
survival (rPFS) for positron emission tomography (PET)-detected, biochemically
recurrent, oligometastatic, castration-sensitive prostate cancer patients treated
with SABR plus placebo vs. SABR plus relugolix.
Patient Population
Pathologically proven diagnosis of prostate adenocarcinoma and are recurrent oligometastatic.
Target Accrual
194
Protocol Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.
Patient Study Webpage
To learn more about this study, visit the Patient Study Webpage.
-
Share this study.
-
-
-
-
